TICKERNERD
Menu
ALTALTHealthcare · Biotechnology

ALT Stock Forecast: Altimmune, Inc. Price Predictions for 2026-2027

Last close, 7 Aug 2026
$3.08
+2.33% on the day

The 10 Wall Street analysts covering Altimmune, Inc. hold a median 12-month price target of $18 — +484.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 8 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$599.0M
Ticker Nerd rank
31 / 100
Median analyst target
$18
Analysts covering
10
Total return, dividends reinvested
1W
+8.5%
1M
+2.0%
YTD
−14.7%
1Y
−12.5%
From 52W high
−50.2%
From 52W low
+18.9%
$2.59
$6.18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Altimmune, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Aug 2026
31 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
89
Revisions
62
Accruals
56
Size
51
Quality
46
Value
32
Volatility
25
Momentum
11
Issuance
8

Growth (89): Sales and profits are climbing, and climbing faster than before.

Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own Altimmune, Inc. — and when they’d sell — is the membership.

Wall Street

ALT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00$30.00Oct 25Jan 26Apr 26Jul 26ALTHigh $28Median $18Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
9 Buy1 Hold0 Sell
Low $11Median $18High $28

The green dot is the last close — the median target sits +484.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 June 2026Leerink PartnersInitiatesOutperform$10
18 May 2026HC Wainwright & Co.MaintainsBuy—
14 May 2026CitizensMaintainsMarket Outperform—
16 Mar 2026HC Wainwright & Co.MaintainsBuy—
6 Mar 2026B. Riley SecuritiesMaintainsBuy—
7 Nov 2025CitizensMaintainsMarket Outperform—
20 Oct 2025HC Wainwright & Co.ReiteratesBuy—
10 Oct 2025HC Wainwright & Co.ReiteratesBuy—
13 Aug 2025B. Riley SecuritiesMaintainsBuy—
13 Aug 2025HC Wainwright & Co.ReiteratesBuy—
13 Aug 2025UBSMaintainsBuy—
10 July 2025JMP SecuritiesMaintainsMarket Outperform—
27 June 2025HC Wainwright & Co.ReiteratesBuy—
3 Apr 2025HC Wainwright & Co.ReiteratesBuy—
2 Apr 2025Citizens Capital MarketsReiteratesMarket Outperform—
18 Mar 2025HC Wainwright & Co.ReiteratesBuy$12
14 Mar 2025Citizens Capital MarketsReiteratesMarket Outperform—
3 Mar 2025HC Wainwright & Co.ReiteratesBuy—
28 Feb 2025William BlairInitiatesMarket Perform—
5 Feb 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

ALT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
0
Fundamentals

Altimmune, Inc. (ALT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.1×

Cheaper than 87% of US stocks

Price / sales
16638.3×

Cheaper than 1% of US stocks

Price / book
1.4×

Cheaper than 59% of US stocks

EV / EBITDA
−3.2×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−267247.2%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−42.7%

Higher than 23% of US stocks

Return on assets
−24.4%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ALT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ALTAltimmune, Inc.$599.0M
31
NVCTNuvectis Pharma, Inc.$597.4M
71
VSTMVerastem, Inc.$592.0M
56
SPRYARS Pharmaceuticals, Inc.$608.9M
11
CTNMContineum Therapeutics, Inc.$582.9M
63
CRMDCorMedix, Inc.$582.9M
67
TECXTectonic Therapeutic, Inc.$579.8M
25
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest ALT news & analysis

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

GlobeNewsWire · 5 Aug 2026neutral

Altimmune announced it will report its second quarter 2026 financial results and provide a business update on August 12, 2026. The company is a late clinical-stage biopharmaceutical firm developing pemvidutide for serious liver diseases.

Why it matters — This announcement provides a date for shareholders to expect the company's next quarterly financial report and any updates on its lead drug candidate, pemvidutide.

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

GlobeNewsWire · 3 Aug 2026positive

Altimmune has initiated the PERFORMA Phase 3 global registrational trial of pemvidutide for patients with MASH, designed to evaluate the drug's effect on fibrosis improvement, MASH resolution, and clinical outcomes.

Why it matters — This marks a major clinical milestone for Altimmune as pemvidutide advances to the final stage of pivotal testing needed for potential regulatory approval in MASH.

Altimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder Transcript

Seeking Alpha · 28 July 2026neutral

Altimmune (ALT) discussed the topline results of its RECLAIM Phase II trial of pemvidutide for alcohol use disorder in a transcript, as reported by Seeking Alpha.

Why it matters — The RECLAIM trial results are a key clinical milestone for pemvidutide, and this discussion provides investors with direct insights into the data and Altimmune's outlook for the program.

Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study

Benzinga · 28 July 2026positive

Altimmune announced positive topline results from its RECLAIM Phase 2 trial of pemvidutide in patients with moderate to severe alcohol use disorder, showing significant alcohol reduction.

Why it matters — This mid-stage success expands pemvidutide's potential beyond metabolic conditions into a new large-market indication, broadening Altimmune's pipeline value.

Altimmune's Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial

MarketBeat · 28 July 2026positive

Altimmune reported positive top-line results from its Phase II RECLAIM trial of pemvidutide in adults with moderate to severe alcohol use disorder, meeting the primary endpoint and several secondary measures after 24 weeks of treatment.

Why it matters — This marks a key clinical milestone for pemvidutide in a new indication beyond metabolic disease, potentially expanding Altimmune's pipeline opportunity.

FAQ

Frequently asked questions about ALT stock

What is the ALT stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Altimmune, Inc. have a median 12-month price target of $18, with estimates ranging from $11 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALT stock a buy right now?

Of the 10 analysts covering Altimmune, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Altimmune, Inc. 31 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALT?

As at 8 Aug 2026, Altimmune, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (89 of 100).

Will ALT stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +484.4% from the last close, and Ticker Nerd's factor model ranks Altimmune, Inc. 31 out of 100 as at 8 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALT stock forecast for 2030?

No analyst covering Altimmune, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $28 over the next 12 months.

How has ALT stock performed over the past year?

Altimmune, Inc. returned -12.5% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Altimmune, Inc. do?

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based therapeutics for obesity, metabolic diseases, and liver diseases.

What is the latest news on ALT?

The most recent item we track (GlobeNewsWire, 5 Aug 2026): "Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026". Altimmune announced it will report its second quarter 2026 financial results and provide a business update on August 12, 2026. The company is a late clinical-stage biopharmaceutical firm developing pemvidutide for serious liver diseases.

Company

About Altimmune, Inc.

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based therapeutics for obesity, metabolic diseases, and liver diseases. Its lead product candidate, pemvidutide, is a novel GLP-1/glucagon dual receptor agonist designed to address obesity and metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH). Pemvidutide activates GLP-1 to suppress appetite and glucagon to increase energy expenditure and promote hepatic fat metabolism, mimicking effects of diet and exercise. The company is advancing pemvidutide in clinical trials for these indications, leveraging its differentiated profile for potential broader applications. Additionally, Altimmune develops HepTcell, an immunotherapeutic aimed at achieving a functional cure for chronic hepatitis B through Phase II trials conducted internationally. Operating wholly owned subsidiaries supports its global development efforts in peptide therapeutics targeting unmet needs in metabolic and liver health sectors. Founded in 1997 and headquartered in Gaithersburg, Maryland, Altimmune focuses on next-generation treatments in these critical therapeutic areas.

CEO Mr. Jerome Benedict Durso · 57 employees · United States · https://altimmune.com